Drugs firm AstraZeneca has said it plans to start earning a “modest” profit from its COVID-19 vaccine having previously sold it at cost.

The Anglo-Swedish company has until now not been making a profit from the Oxford coronavirus jab and said it would not do so during the pandemic.

The vaccine has in fact proved a drag on earnings so far this year according to latest financial results.

AZ said it had supplied $2.22bn worth of the drug, representing delivery of 580 million doses, in the first nine months of 2021 – including $1.05bn in the third quarter.

When including partners sub-licensed to make the vaccine it has released 1.5bn doses for supply in more than 170 countries, the company said.

It said that it was “now expecting to progressively transition the vaccine to modest profitability as new orders are received”.

That will result in a “limited” profit contribution from the last three months of this year though the “large majority” of sales in the period will come from agreements already in place, AZ said.

China’s Singles’ Day sees sales growth slow as ‘worship of turnover’ criticised

‘Without coal this area cannot exist’: The impoverished who rely on India’s mining industry after COP26 pledge to go net zero by 2070

Climate Crisis: Sky News presenter Adam Boulton tries out hydrogen-powered digger and two-seater car

The results showed that, over the year-to-date, the company’s profit margins have shrunk compared to last year “predominantly reflecting the equitable supply, at no profit to AstraZeneca, of the pandemic COVID-19 vaccine”.

However for the third quarter the vaccine did make a small positive contribution to earnings.

AstraZeneca said its revenues for the quarter rose 50% to $9.87bn.

But profits fell short of expectations as the costs of integrating rare disease specialist Alexion, following a takeover, as well as a writedown on an experimental kidney treatment and investments into its drug pipeline took their toll.

In contrast, US rival Pfizer recently said that it expected to enjoy margins in the “high-20s” as a percentage of sales of the COVID-19 vaccine it developed with Germany’s BioNTech.

Those sales are expected to total $36bn this year.

Related posts:

Pandemic drives insurance costs down to ‘lowest level since 2015’ Owner kicks off £100m sale to fire up Engine Group Help for high streets as retail sales surge 9.2% after lockdown hibernation ends Afghanistan is one of the poorest countries in the world – now things could get even worse Ministers hire JP Morgan to screen options for future of Channel 4 John Lewis and Waitrose owner hires thousands more temporary workers ahead of Christmas Wagamama owner warns of price rises as it becomes latest to flag supply chain pressures Pubs industry veteran Findlay to chair Magners owner C&C Group Co-op warns profits under pressure due to supply chain challenges Horror show for Cineworld as £722m court ruling sends shares tumbling Springsteen is latest to sell back catalogue – but are investors dancing in the dark? Retail sales jump in November with Black Friday boost